Trading Statement

Byotrol plc
                  

                      Byotrol plc ('the Company')
                            Trading Update

The board of Byotrol is pleased with the progress that the Company has made in
the four months since its flotation on AIM in July 2005. Sales for the period to
30 September 2005, although still modest, have exceeded budget and costs have
been controlled in line with budget.

NHS trial

The Company has initiated a four-month trial with a major NHS hospital to study
the efficacy of its technology in reducing the spread of hospital acquired MRSA.
If successful, the Directors are confident that Byotrol's technology and
products will find very wide acceptance and use in hospitals and other
healthcare facilities across the NHS.

EPA update

In the USA the Company has completed, on time, the first (formulation and scope
testing) stage of its three stage plan to achieve EPA approval for the US food
processing and healthcare markets. The Directors believe product approvals for
these markets will be obtained in the first half of 2006. Byotrol materials,
using current EPA accepted labeling, have been supplied and successfully used in
the cleanup operations following Hurricane Katrina.

European registrations

To facilitate future pan European sales the Company has commenced the European
Union's CE mark approval process for three healthcare products that use Byotrol
materials. The Company expects to achieve CE mark status in the next six to nine
months.

Street furniture

Additionally, following a successful trial in Bournemouth, a Byotrol based
coating has been specified for use in the maintenance of street furniture and
lampposts by Southern Electric Contracting Limited, the public lighting and
maintenance contracting subsidiary of Scottish and Southern Energy plc. The
addition of Byotrol's anti-microbial products was found to have considerable
cost and public safety advantages.

Distribution agreement

In Europe the Company has recently entered into a memorandum of understanding
which is expected to lead to a distribution agreement with Exa Consultancy in
Sweden. This agreement covers sales of Byotrol products in the domestic,
technical and food markets. This complements a food industry supply arrangement
agreed with Dykorn AS in Norway in September.

Interim results

The Company will report its interim results for the period to 30 September 2005
in early December and will provide a further update on progress at that time.

--  ends -

Media calls to:

Jim Rothnie
McCann Erickson PR
T: 01625 822540
E: [e-mail]

Financial enquiries to:

Nick Rodgers or Oli Rayner
Merchant Capital
0207 332 2200